**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 75547

**Manuscript Type:** CASE REPORT

**Incidental diagnosis of medullary thyroid carcinoma due to persistently elevated procalcitonin in a patient with COVID-19 pneumonia: A case report**

Saha A *et al*. Incidental MTC from procalcitonemia in COVID-19

Amitabha Saha, Madhusha Mukhopadhyay, Souvik Paul, Arnab Bera, Tapas Bandyopadhyay

**Amitabha Saha,** Department of Internal Medicine, Critical Care Medicine, Medica Superspecialty Hospital, Kolkata 700099, West Bengal, India

**Madhusha Mukhopadhyay, Tapas Bandyopadhyay,** Department of Internal Medicine, Medica Superspecialty Hospital, Kolkata 700099, West Bengal, India

**Souvik Paul, Arnab Bera,** Department of Critical Care Medicine, Medica Superspecialty Hospital, Kolkata 700099, West Bengal, India

**Author contributions:** Saha A, Paul S, and Bandyopadhyay T took care of the patient; Amitabha Saha A and Mukhopadhyay M conceived the idea for the study; Mukhopadhyay M, Paul S, and Bera A conducted the research and data collection; Mukhopadhyay M, Saha A, Bera A, and Bandyopadhyay T drafted, proofread, and formatted the manuscript; All authors issued final approval for the version to be submitted.

**Corresponding author: Madhusha Mukhopadhyay, DNB, MRCP, Attending Doctor, Staff Physician,** Department of Internal Medicine, Medica Superspecialty Hospital, 127 E M Bypass, Nitai Nagar, Kolkata 700099, West Bengal, India. madhusha.mukhopadhyay@rediffmail.com

**Received:** February 4, 2022

**Revised:** April 13, 2022

**Accepted:** May 17, 2022

**Published online:** July 16, 2022

**Abstract**

BACKGROUND

Procalcitonin (Pct) is a common biomarker in clinical practice, especially in the era of coronavirus disease 2019 (COVID-19) infection. Although it is frequently used for the diagnosis and prognostication of bacterial infections or sepsis, it is also elevated in a few other conditions, including medullary thyroid carcinoma (MTC).

CASE SUMMARY

A 43-year-old female presented with moderately severe COVID-19 pneumonia in April 2021. She gradually recovered clinically; however, despite normalization of other inflammatory markers, Pct levels remained persistently elevated. Further workup identified the cause as left lobe MTC with locoregional metastasis. Calcitonin levels were high, and carcinoembryonic antigen levels were normal. The patient underwent total thyroidectomy and neck dissection, which was followed by another radical neck dissection due to residual disease. Currently, she is doing well, nearly having completed her course of external beam radiotherapy with no recurrence. Pct is well documented as a screening tool for MTC, especially because of its stable nature compared to calcitonin in the community settings. It is important to keep in mind the differential diagnosis of MTC in patients with persistently elevated Pct levels despite normal levels of other acute phase reactants. To the best of our knowledge, this is the first report from Asia of such an incidental diagnosis of MTC due to persistently elevated Pct levels in a patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

CONCLUSION

Persistently elevated Pct levels can occur in any pro-inflammatory state including infections, sepsis, or acute respiratory distress syndrome. In the current setting, SARS-CoV-2 infection is one such clinical scenario, and in rare situations of persistent elevation, MTC may need to be ruled out.

**Key Words:** COVID-19; Medullary thyroid carcinoma; Procalcitonin; SARS-COV-2; Calcitonin; Case report

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Saha A, Mukhopadhyay M, Paul S, Bera A, Bandyopadhyay T. Incidental diagnosis of medullary thyroid carcinoma due to persistently elevated procalcitonin in a patient with covid-19 pneumonia: A case report. *World J Clin Cases* 2022; 10(20): 7171-7177

**URL:** https://www.wjgnet.com/2307-8960/full/v10/i20/7171.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i20.7171

**Core Tip:** Procalcitonin (Pct) is a biomarker used very commonly for infections in our clinical practice. It is routinely used in coronavirus disease 2019-infected patients. In this setting, persistent Pct elevation despite normalization of other inflammatory markers may present a diagnostic dilemma. This case highlights the importance of identifying occult medullary thyroid carcinoma in such situations, which would otherwise have been missed and left untreated. In our patient, this led to proper treatment and a successful outcome.

**INTRODUCTION**

Over the last 2 years, coronavirus disease 2019 (COVID-19) has emerged as a global pandemic affecting millions of people. National healthcare systems have been stretched to their limits. In many countries, critical care teams have been overwhelmed by the pandemic, with high requirements for ventilators and life support machines[1-3]. During the course of this disease, several inflammatory biomarkers are commonly elevated and provide a prognostic assessment of the clinical course. Procalcitonin (Pct) is a common biomarker used in clinical practice and is found at extremely low levels in healthy individuals. It is commonly used to distinguish bacterial infections from other causes of infection or inflammation[4,5].

In the absence of systemic inflammation caused by bacterial infection, Pct is synthesized by thyroid neuroendocrine cells and is a precursor of calcitonin (Ctn). Some studies have advocated the use of Pct levels as a screening tool in the diagnosis and follow-up of medullary thyroid carcinoma (MTC)[6-8]. This is especially true because Pct is easier to measure at the community level[9]. In patients with systemic inflammatory responses, elevated Pct levels are common in clinical practice. In our experience, Pct levels often correlate with the severity and outcomes of patients infected with severe acute respiratory syndrome coronavirus 2[10,11].

Herein, we present a case of occult MTC diagnosed because of a persistently elevated Pct level in a patient with COVID-19 pneumonia.

**CASE PRESENTATION**

***Chief complaints***

A 43-year-old woman presented with fever associated with a dry cough for 10 d in April 2021.

***History of present illness***

She complained of mild respiratory distress, and her peripheral capillary oxygen saturation (SpO2) recorded at home was 88%-89%. Three days earlier, she was diagnosed with reverse transcription-polymerase chain reaction confirmed COVID-19.

***History of past illness***

She did not have any significant comorbidities, except for polycystic ovarian disease.

***Personal and family history***

No significant family history or personal history was present.

***Physical examination***

On presentation, the patient had a blood pressure of 140/90 mmHg, pulse rate of 88 beats/min, respiratory rate of 20 breaths/min, and SpO2 of 92% in room air. Lung examination revealed a bilateral decrease in air entry.

***Laboratory examinations***

Initial blood investigations revealed a total leucocyte count of 11650 cells/µL (neutrophils 88% and lymphocytes 8%) (normal: 4000-11000 cells/µL), C-reactive protein (CRP) of 16.44 mg/L (normal: < 10 mg/L), Pct of 9.52 ng/mL (normal: < 0.1 ng/mL), lactate dehydrogenase of 282 IU/L (normal: 105-333 IU/L), ferritin of 158 ng/mL (normal: males: 12-300 ng/mL; females: 12-150 ng/mL), D-dimer of 775.84 ng/mL (normal: < 500 ng/mL), interleukin-6 of 18.55 pg/mL (normal: 0-7 pg/mL), and slightly elevated liver enzymes. Electrolyte and renal function test results were normal. Arterial blood gas analysis confirmed severe hypoxia with an arterial oxygen partial pressure of 39.0 mmHg (normal: 75-100 mmHg).

***Imaging examinations***

High-resolution computed tomography (CT) of the chest confirmed atypical viral infection with approximately 50% lung involvement with a CT severity index (CTSI) score of 18/25 (COVID-19 Reporting and Data System 5/5). The patient was placed on a non-rebreather mask with 15 L/min of oxygen, to which she maintained 100% oxygen saturation. Echocardiography revealed no cardiac issues with an ejection fraction of 60%.

***Clinical course and further diagnostic work-up***

She underwent chest physiotherapy and incentive spirometry. She was started on a course of intravenous (IV) remdesivir, IV dexamethasone, oral doxycycline, low molecular weight heparin, multivitamins, antibiotics, and appropriate nebulization. Over the next 7 d, she gradually improved, and her oxygen requirement decreased. Chest CT was repeated on day 8, and the CTSI score was 12/25. On day 12, she was weaned off oxygen, and all reports normalized except the Pct level, which was persistently elevated (Table 1, Figure 1). Since she was clinically stable, she was subsequently discharged with a plan of investigating the persistently elevated Pct level on an outpatient basis.

Due to persistently elevated Pct level on follow-up, with no other clinical signs of infection, she was evaluated for other possible causes of elevated Pct. The neck examination results were unremarkable. Ultrasonography of the neck, however, revealed a 15.7 mm × 15 mm nodule in the left lobe of the thyroid gland, and fine-needle aspiration cytology (FNAC) confirmed a malignant epithelial neoplasm (The Bethesda System for Reporting Thyroid Cytopathology VI). FNAC of the left supraclavicular node confirmed metastatic carcinoma. The Ctn level was 406 pg/mL (normal: < 10 pg/mL). Carcinoembryonic antigen (CEA) was not elevated. Positron emission tomography-CT (PET-CT) confirmed the presence of a well-defined inhomogeneously enhancing fluorodeoxyglucose-avid (maximum standardized uptake value: 4.8) nodule in the left lobe of the thyroid gland measuring 18 mm × 13 mm with no evidence of distant spread (Figure 2).

**FINAL DIAGNOSIS**

A final diagnosis of MTC was confirmed in a patient with COVID-19 pneumonia and persistently elevated Pct.

**TREATMENT**

The initial surgery was performed in July 2021 and comprised total thyroidectomy and central lymph node dissection. The left lobe contained a single nodule measuring 3 cm × 2 cm x 1.5 cm. The right lobe and isthmus were unremarkable. Histological examination confirmed the presence of MTC with lymphovascular invasion. Eleven of the fourteen lymph nodes examined were positive from the neck dissection (American Joint Committee on Cancer stage III, pT2N1M0).

Postoperatively, due to persistently elevated Ctn (189 pg/mL), a PET-CT scan was repeated, and she was advised to undergo a second radical neck dissection, wherein six positive nodes out of 16 lymph nodes were successfully removed. Subsequently, the Pct and Ctn levels dropped to 3.54 ng/mL and 14 pg/mL, respectively. Multiple endocrine neoplasia type II (MEN-2) syndrome was ruled out due to negative family history, relevant normal laboratory parameters, and negative Rearranged during Transfection (*RET*)gene mutation analysis.

**OUTCOME AND FOLLOW-UP**

Six months have elapsed since her first surgery. She is currently doing well and is on 150 mcg/d levothyroxine supplementation with a successful external beam radiotherapy (EBRT) regimen without any current evidence of recurrence.

**DISCUSSION**

This is an unusual presentation of an incidental diagnosis of MTC in a patient with COVID-19 pneumonia. In this patient, serum Pct levels remained persistently high despite normalization of the remaining acute phase reactants, which led to subsequent investigation and diagnosis. Eventually, this allowed the patient to receive complete treatment, which would otherwise not have been possible. Thus, a high Pct combined with normal CRP or other indicators of sepsis warrants a differential diagnosis of MTC.

The workup of MTC includes measurement of serum Ctn, CEA, ultrasonography of the neck, PET-CT, appropriate genetic testing for *RET* mutations, and evaluation of other tumors related to MEN-2 syndrome[12]. In our patient, the Ctn level was elevated, while the CEA level was normal. Ultrasonography revealed locoregional disease, and PET-CT and mammography ruled out distant metastasis. MEN-2 syndrome was ruled out based on history, biochemical parameters, and negative *RET* mutation analysis. FNAC confirmed the diagnosis, and successful surgery was performed, followed by postoperative EBRT, as indicated.

Ctn is a hormone produced by the parafollicular cells of the thyroid gland and is therefore used as a marker for MTC. Ctn is present in multiple heterogeneous forms and is synthesized from a prohormone, Pct. Pct is a 116-amino acid prohormone comprising three peptides, and its subsequent enzymatic processing produces Ctn as a byproduct[13]. Some of the differential diagnoses of increased Ctn precursors in the blood (including Pct) are summarized in Table 2.

Azevedo *et al*[14] evaluated the concordance between Ctn and Pct values in 41 patients with MTC and concluded that they were strongly correlated with each other. Machens *et al*[9] studied 457 patients with MTC and concluded that serum Pct could potentially replace Ctn as a screening biomarker, especially in a community setting, because the samples did not need to be kept frozen or on ice. Unlike Ctn, Pct is a very stable protein with a concentration-independent *in vivo* half-life of 20-24 h[7]. Karagiannis *et al*[8] performed a systematic review of Pct as an MTC marker. Among the 15 studies (including three case reports) assessed, the suggestion was that Pct was a useful biomarker, with an acceptable cut-off of 0.1 ng/mL in everyday clinical practice. Ctn was considered the best primary biomarker, with Pct as an adjunct, per clinical indication. Giovanella *et al*[6] reviewed 2705 patients with thyroid nodules and concluded that the Pct level was a sensitive and accurate method of screening for MTC.

The sensitivity and specificity of Ctn for the diagnosis of MTC are high (> 90%), whereas they are much lower for Pct, as seen in Table 2[15-18]. Hence, while Pct, a much more stable compound, may be more useful as a screening test at the community level, Ctn remains the best diagnostic screening tool for MTC[7]. However, because Pct is a more common investigation in a hospital setting due to its varied usefulness, there are some reports of MTC diagnosis due to elevated Pct. In the context of COVID-19 infection, two isolated case reports have been reported in Europe[19,20]. To the best of our knowledge, this is the first report from Asia of an incidental diagnosis of MTC due to persistently elevated Pct. Our patient was diagnosed with a locoregional disease which was successfully operated on and is currently doing well.

**CONCLUSION**

In conclusion, it is important to consider the differential diagnosis of MTC in patients with persistently elevated Pct despite normal levels of other acute phase reactants. This can occur in any pro-inflammatory state, including infection, sepsis, or acute respiratory distress syndrome. In the current setting, COVID-19 infection is a clinical scenario where Pct elevation is common, and in rare situations of persistent elevation, MTC may need to be ruled out.

**REFERENCES**

1 **World Health Organization**. WHO Coronavirus (COVID-19) Dashboard. [cited April 1, 2022]. Available online: https://covid19.who.int/

2 **Badulak J**, Antonini MV, Stead CM, Shekerdemian L, Raman L, Paden ML, Agerstrand C, Bartlett RH, Barrett N, Combes A, Lorusso R, Mueller T, Ogino MT, Peek G, Pellegrino V, Rabie AA, Salazar L, Schmidt M, Shekar K, MacLaren G, Brodie D; ELSO COVID-19 Working Group Members. Extracorporeal Membrane Oxygenation for COVID-19: Updated 2021 Guidelines from the Extracorporeal Life Support Organization. *ASAIO J* 2021; **67**: 485-495 [PMID: 33657573 DOI: 10.1097/MAT.0000000000001422]

3 **Carbonell R**, Urgelés S, Rodríguez A, Bodí M, Martín-Loeches I, Solé-Violán J, Díaz E, Gómez J, Trefler S, Vallverdú M, Murcia J, Albaya A, Loza A, Socias L, Ballesteros JC, Papiol E, Viña L, Sancho S, Nieto M, Lorente MDC, Badallo O, Fraile V, Arméstar F, Estella A, Sanchez L, Sancho I, Margarit A, Moreno G; COVID-19 SEMICYUC Working Group. Mortality comparison between the first and second/third waves among 3,795 critical COVID-19 patients with pneumonia admitted to the ICU: A multicentre retrospective cohort study. *Lancet Reg Health Eur* 2021; **11**: 100243 [PMID: 34751263 DOI: 10.1016/j.lanepe.2021.100243]

4 **Kamat IS**, Ramachandran V, Eswaran H, Guffey D, Musher DM. Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis. *Clin Infect Dis* 2020; **70**: 538-542 [PMID: 31241140 DOI: 10.1093/cid/ciz545]

5 **Han J**, Gatheral T, Williams C. Procalcitonin for patient stratification and identification of bacterial co-infection in COVID-19. *Clin Med (Lond)* 2020; **20**: e47 [PMID: 32414743 DOI: 10.7861/clinmed.Let.20.3.3]

6 **Giovanella L**, Imperiali M, Piccardo A, Taborelli M, Verburg FA, Daurizio F, Trimboli P. Procalcitonin measurement to screen medullary thyroid carcinoma: A prospective evaluation in a series of 2705 patients with thyroid nodules. *Eur J Clin Invest* 2018; **48**: e12934 [PMID: 29635700 DOI: 10.1111/eci.12934]

7 **Algeciras-Schimnich A**, Preissner CM, Theobald JP, Finseth MS, Grebe SK. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. *J Clin Endocrinol Metab* 2009; **94**: 861-868 [PMID: 19088163 DOI: 10.1210/jc.2008-1862]

8 **Karagiannis AK**, Girio-Fragkoulakis C, Nakouti T. Procalcitonin: A New Biomarker for Medullary Thyroid Cancer? A Systematic Review. *Anticancer Res* 2016; **36**: 3803-3810 [PMID: 27466480]

9 **Machens A**, Lorenz K, Dralle H. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer. *J Clin Endocrinol Metab* 2014; **99**: 2986-2994 [PMID: 24840813 DOI: 10.1210/jc.2014-1278]

10 **Hu R**, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. *Int J Antimicrob Agents* 2020; **56**: 106051 [PMID: 32534186 DOI: 10.1016/j.ijantimicag.2020.106051]

11 **Lippi G**, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. *Clin Chim Acta* 2020; **505**: 190-191 [PMID: 32145275 DOI: 10.1016/j.cca.2020.03.004]

12 **Thomas CM**, Asa SL, Ezzat S, Sawka AM, Goldstein D. Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines. *Curr Oncol* 2019; **26**: 338-344 [PMID: 31708652 DOI: 10.3747/co.26.5539]

13 **Becker KL**, Nylén ES, White JC, Müller B, Snider RH Jr. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. *J Clin Endocrinol Metab* 2004; **89**: 1512-1525 [PMID: 15070906 DOI: 10.1210/jc.2002-021444]

14 **Azevedo T**, Martinho M, Martins T, Cunha N, Valido F, Rodrigues F. Procalcitonin: a promising role in medullary thyroid carcinoma? *Endocrine* 2010; **22**: P836

15 **Verbeek HH**, de Groot JWB, Sluiter WJ, Muller Kobold AC, van den Heuvel ER, Plukker JT, Links TP. Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules. *Cochrane Database Syst Rev* 2020; **3**: CD010159 [PMID: 32176812 DOI: 10.1002/14651858.CD010159.pub2]

16 **Karges W**. Calcitonin determination for early diagnosis of medullary thyroid cancer. *Chirurg* 2010; **81**: 620, 622-626 [PMID: 20549176 DOI: 10.1007/s00104-009-1883-9]

17 **Niederle MB**, Scheuba C, Riss P, Selberherr A, Koperek O, Niederle B. Early Diagnosis of Medullary Thyroid Cancer: Are Calcitonin Stimulation Tests Still Indicated in the Era of Highly Sensitive Calcitonin Immunoassays? *Thyroid* 2020; **30**: 974-984 [PMID: 32056502 DOI: 10.1089/thy.2019.0785]

18 **Trimboli P**, Seregni E, Treglia G, Alevizaki M, Giovanella L. Procalcitonin for detecting medullary thyroid carcinoma: a systematic review. *Endocr Relat Cancer* 2015; **22**: R157-R164 [PMID: 25934688 DOI: 10.1530/ERC-15-0156]

19 **Gianotti L**, D'Agnano S, Pettiti G, Tassone F, Giraudo G, Lauro C, Lauria G, Del Bono V, Borretta G. Persistence of Elevated Procalcitonin in a Patient with Coronavirus Disease 2019 Uncovered a Diagnosis of Medullary Thyroid Carcinoma. *AACE Clin Case Rep* 2021; **7**: 288-292 [PMID: 33997278 DOI: 10.1016/j.aace.2021.05.001]

20 **Sira L**, Balogh Z, Vitális E, Kovács D, Győry F, Molnár C, Bodor M, Nagy EV. Case Report: Medullary Thyroid Cancer Workup Initiated by Unexpectedly High Procalcitonin Level-Endocrine Training Saves Life in the COVID-19 Unit. *Front Endocrinol (Lausanne)* 2021; **12**: 727320 [PMID: 34707568 DOI: 10.3389/fendo.2021.727320]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for the publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** February 4, 2022

**First decision:** March 23, 2022

**Article in press:** May 17, 2022

**Specialty type:** Medicine, general and internal

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Ata F, Qatar; Tiejun W, China**A-Editor:** Lin FY **S-Editor:** Ma YJ **L-Editor:** Filipodia **P-Editor:** Ma YJ

**Figure Legends**



**Figure 1 Graph of** **procalcitonin *vs* C-reactive protein during admission and procalcitonin drop postoperatively (she was operated at 140 d since her first admission).** procalcitonin measured in ng/mL; C-reactive protein in mg/L. Pct: procalcitonin; CRP: C-reactive protein.

****

**Figure 2 Axial (A) and coronal (B) sections of positron emission tomography-computed tomography showing positive uptake of fluorodeoxyglucose in the left lobe of the thyroid gland.**

**Table 1 Serial measurements while hospitalized and first follow-up of white blood cell count, procalcitonin, C-reactive protein, and D-dimer levels**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Day from admission** | **WBC, cells/µL** | **Pct, ng/mL** | **CRP, mg/L** | **D-dimer, ng/mL** |
| 2 | 11650 | 9.52 | 16.44 | 775.84 |
| 5 | 4690 | 8.94 | 25.92 | 890.35 |
| 8 | 8070 | 9.42 | 3.52 |  |
| 12 | 12400 | 9.82 | 3.31 | 456.61 |
| 16 | 8240 | 11.6 | 3.08 |  |
| 19 (Discharge) |  | 13.1 | 2.71 |  |
| 24 | 3720 | 16.69 | 2.77 | 0.14 |
| 50 | 5850 | 16.21 | 0.67 |  |

CRP: C-reactive protein; Pct: procalcitonin; WBC: white blood cell count.

**Table 2 Differential diagnoses of increased procalcitonin**

|  |
| --- |
| Bacterial infection or sepsis |
| Medullary thyroid carcinoma |
| Acute respiratory disease syndrome |
| Pulmonary neuroendocrine hyperplasia |
| Aspiration pneumonia |
| Small cell or non-small cell cancer of the lung |
| Carcinoid tumor |
| Other neuroendocrine tumors |
| Breast cancer |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**